Pulmonary hypertension (PH) is a progressive disease characterized by severe remodeling of the distal pulmonary vasculature; without treatment, the condition leads irremediably to death through right ventricular failure.
In this issue of ePulmonology Review, Paul M. Hassoun, MD, Professor of Medicine and Director of the Pulmonary Hypertension Program at The Johns Hopkins University School of Medicine in Baltimore, reviews and analyzes the current literature redefining and reclassifying PH and the most recent evidence (both pharmacological and pharmacoeconomic) supporting the use of up-front combination therapy vs monotherapy in patients with pulmonary arterial hypertension (PAH).
Professor of Medicine Director
Pulmonary Hypertension Program
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: August 14, 2018
Expiration date: August 13, 2020